Kangmei Pharmaceutical Co., Ltd. (SHA:600518)
China · Delayed Price · Currency is CNY 1.710
-0.020 (-1.16%)
Apr 30, 2026, 3:00 PM CST
Kangmei Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 5,252 | 5,151 | 4,827 | 4,161 | 4,054 |
Other Revenue | - | 38.35 | 47.3 | 18.95 | 98.79 |
| 5,252 | 5,189 | 4,874 | 4,180 | 4,153 | |
Revenue Growth (YoY) | 1.22% | 6.46% | 16.60% | 0.66% | -23.27% |
Cost of Revenue | 4,203 | 4,536 | 4,145 | 3,749 | 4,061 |
Gross Profit | 1,049 | 653.37 | 728.86 | 431.14 | 91.52 |
Selling, General & Admin | 1,039 | 959.78 | 1,054 | 1,037 | 1,283 |
Research & Development | 45.33 | 51.46 | 45.62 | 25.45 | 9.27 |
Other Operating Expenses | -147.03 | 30.76 | -311.78 | 195.22 | 653.49 |
Operating Expenses | 937.45 | 1,067 | 549.27 | 1,471 | 3,138 |
Operating Income | 111.68 | -413.53 | 179.59 | -1,040 | -3,046 |
Interest Expense | - | -21.39 | -56.15 | -78.9 | -1,022 |
Interest & Investment Income | 90.6 | 76.41 | 75.18 | 40.77 | 194.06 |
Currency Exchange Gain (Loss) | - | - | - | - | -0.02 |
Other Non Operating Income (Expenses) | 24.36 | 22.74 | -34.04 | -16.04 | -1,041 |
EBT Excluding Unusual Items | 226.65 | -335.77 | 164.57 | -1,095 | -4,915 |
Gain (Loss) on Sale of Investments | 0.01 | -0 | -0.03 | - | - |
Gain (Loss) on Sale of Assets | 0.85 | 39.47 | 19.61 | 0.98 | 64.01 |
Asset Writedown | -184.38 | -31.47 | -99.69 | -307.46 | -2,634 |
Legal Settlements | - | -8.66 | -12.12 | -331.49 | -1,576 |
Other Unusual Items | - | 371.07 | 38.03 | -931.58 | 17,217 |
Pretax Income | 43.12 | 34.65 | 110.37 | -2,664 | 8,155 |
Income Tax Expense | 30.69 | 22.57 | 6.8 | 29.75 | 235.39 |
Earnings From Continuing Operations | 12.43 | 12.08 | 103.57 | -2,694 | 7,920 |
Minority Interest in Earnings | -2.1 | -3.51 | -1.05 | 5.64 | -2 |
Net Income | 10.33 | 8.57 | 102.52 | -2,688 | 7,918 |
Net Income to Common | 10.33 | 8.57 | 102.52 | -2,688 | 7,918 |
Net Income Growth | 20.46% | -91.64% | - | - | - |
Shares Outstanding (Basic) | 14,754 | 14,289 | 10,252 | 14,148 | 13,891 |
Shares Outstanding (Diluted) | 14,754 | 14,289 | 10,252 | 14,148 | 13,891 |
Shares Change (YoY) | 3.25% | 39.38% | -27.54% | 1.85% | 0.55% |
EPS (Basic) | 0.00 | 0.00 | 0.01 | -0.19 | 0.57 |
EPS (Diluted) | 0.00 | 0.00 | 0.01 | -0.19 | 0.57 |
EPS Growth | 16.67% | -94.00% | - | - | - |
Free Cash Flow | -105.71 | -489.34 | -417.27 | -798.08 | 42.58 |
Free Cash Flow Per Share | -0.01 | -0.03 | -0.04 | -0.06 | 0.00 |
Gross Margin | 19.98% | 12.59% | 14.95% | 10.31% | 2.20% |
Operating Margin | 2.13% | -7.97% | 3.69% | -24.89% | -73.37% |
Profit Margin | 0.20% | 0.17% | 2.10% | -64.31% | 190.68% |
Free Cash Flow Margin | -2.01% | -9.43% | -8.56% | -19.09% | 1.03% |
EBITDA | 389.44 | -131.8 | 470.91 | -730.42 | -2,493 |
EBITDA Margin | 7.41% | -2.54% | 9.66% | -17.47% | -60.04% |
D&A For EBITDA | 277.76 | 281.73 | 291.32 | 309.93 | 553.19 |
EBIT | 111.68 | -413.53 | 179.59 | -1,040 | -3,046 |
EBIT Margin | 2.13% | -7.97% | 3.68% | -24.89% | -73.37% |
Effective Tax Rate | 71.17% | 65.13% | 6.16% | - | 2.89% |
Revenue as Reported | - | 5,189 | 4,874 | 4,180 | 4,153 |
Advertising Expenses | - | 55.26 | 193.19 | 114.06 | 99.5 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.